Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PiSARRO trial of APR-246 added to carboplatin + pegylated liposomal doxorubicin in recurrent high grade serous ovarian cancer
NL-OMON47287Phase 2Active, not recruiting
- Sponsor
- Aprea Therapeutics
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of eprenetapopt in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Aprea Therapeutics. Primary endpoint: Progression-free survival. Started Sep 2016; status: active, not recruiting.
02
Drugs
eprenetapopt
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NL-OMON47287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47287.